The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface-Reference-Cited by-同舟云学术

The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface

Published:2014-07-22 Issue:7 Volume:9 Page:e103254
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lee Fuiyee,Luevano Martha,Veys Paul,Yong Kwee,Madrigal Alejandro,Shaw Bronwen E.,Saudemont Aurore

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report;AH Filipovich;Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation,2005

2. Reshaping human antibodies for therapy;L Riechmann;Nature,1988

3. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes;G Hale;Journal of immunology,1985

4. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen;MQ Xia;Molecular immunology,1993

5. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism;AP Mone;Leukemia,2006

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M);The Patient - Patient-Centered Outcomes Research;2021-05-31

2. Targeting T Follicular Helper Cells to Control Humoral Allogeneic Immunity;Transplantation;2021-04-01

3. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data;International Journal of STD & AIDS;2021-02-18

4. Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis;Frontiers in Immunology;2020-01-31

5. Brief Report: CD52 Expression on CD4+ T Cells in HIV-Positive Individuals on cART;JAIDS Journal of Acquired Immune Deficiency Syndromes;2018-02-01